Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Marker and kit for auxiliary diagnosis of prostatic cancer

A technology for prostate cancer and auxiliary diagnosis, which is applied in the field of medicine and biology, can solve the problems of lack of specific diagnostic indicators, etc., and achieve the effects of inhibiting growth, inhibiting proliferation, and promoting proliferation

Active Publication Date: 2021-10-01
PEOPLES HOSPITAL OF HENAN PROV
View PDF4 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The treatment of early prostate cancer is radical surgery, but because most early prostate cancer has no obvious symptoms and lacks specific diagnostic indicators, most patients are already diagnosed with advanced prostate cancer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Marker and kit for auxiliary diagnosis of prostatic cancer
  • Marker and kit for auxiliary diagnosis of prostatic cancer
  • Marker and kit for auxiliary diagnosis of prostatic cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0061] Example 1: Study on the Expression of LncRNA SNHG11 in Prostate Cancer Tissues and Their Matched Paracancerous Normal Tissues

[0062] 1. Sample collection:

[0063] Collect 60 cases of histopathologically confirmed primary prostate cancer cancer tissue and corresponding adjacent normal tissue samples > 3cm. In order to prevent the degradation of RNA, the specimens were cut immediately after surgical resection, and washed twice with PBS. Put it into a cryopreservation tube and put it into liquid nitrogen immediately, and finally transfer it to a -80°C refrigerator for long-term storage. None of the 60 prostate cancer patients received radiotherapy and chemotherapy before surgery, and surgery was the preferred treatment option. According to the system stipulated by the ethics review committee, each patient signed an informed consent form before sampling.

[0064] 2. Experimental method

[0065] qRT-PCR was used to detect the expression level of LncRNA SNHG11 in the ca...

Embodiment 2

[0107] Example 2: Study on the expression of LncRNA SNHG11 in prostate cancer cells and normal prostate cell lines

[0108] 1. Cell selection and culture:

[0109] Human normal prostate cell line RWPE-1, prostate cancer cell lines LNCaP, 22RV1, DU145, PC-3 were cultured; the cells were routinely cultured in 1640 cell culture medium containing 10% FBS, 1% penicillin and streptomycin, in which RWPE-1 uses KM medium, PC-3 uses F-12K medium instead of 1640 medium, and the five kinds of cells are stored at 37°C and 5% CO 2 and cultured under conditions of saturated humidity. The cells were replaced every 2 days and passaged at a ratio of 1:3.

[0110] 2. Experimental method:

[0111] qRT-PCR was used to detect the expression level of LncRNA SNHG11 in prostate cancer cells and normal prostate cell lines, and the specific steps were as follows:

[0112] (1) Extraction of cellular RNA:

[0113] Total cellular RNA was extracted by TRIzo1 method.

[0114] Collect the cells in the ...

Embodiment 3

[0124] Example 3: Knockout of LncRNA SNHG11 Gene

[0125] 1. Cell culture:

[0126] Human prostate cancer cell lines DU145 and PC-3 were cultured in 1640 cell culture medium and F-12K medium containing 10% fetal bovine serum and 1% penicillin and streptomycin at 37°C and 5% CO respectively. 2 , Cultivated in an incubator with a relative humidity of 90%. The cells were changed every 2 days, and digested and passaged with digestive enzymes.

[0127] 2.siRNA design

[0128] siRNA sequence against LncRNA SNHG11 gene:

[0129] Negative control siRNA (referred to as siNC) sequence:

[0130] The sense strand of siNC is: 5'-UUCUCCGAACGUGUCACGUTT-3';

[0131] The antisense strand of siNC is: 5'-ACGUGACACGUUCGGAGAATT-3'.

[0132] siRNA 1:

[0133] The sense strand of siRNA 1 is: 5'-GCACUAGAGAGAGCGUCUUGU-3' (SEQ ID NO.4);

[0134] The antisense strand of siRNA 1 is: 5'-ACAAGACGCUCUCUCUAGUGC-3' (SEQ ID NO.5).

[0135] siRNA 2:

[0136]The sense strand of siRNA 2 is: 5'-GGCUAUCCU...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of medical biology, and discloses a molecular marker-LncRNA SNHG11 for auxiliary diagnosis of prostatic cancer. The LncRNA SNHG11 is highly expressed in cancer tissues of prostatic cancer, and is lowly expressed in paracancerous normal tissues; moreover, the expression level of the LncRNA SNHG11 in a prostatic cancer cell line is obviously higher than that of a normal prostate cell line; proliferation, migration and invasion of prostatic cancer cells can be obviously inhibited by knocking down the expression level of the LncRNA SNHG11 gene. Therefore, the LncRNA SNHG11 can be used as a molecular marker for auxiliary diagnosis of the prostatic cancer; by detecting the expression level of the LncRNA SNHG11 in a sample, auxiliary diagnosis can be carried out on the prostatic cancer, and a reference basis is provided for clinical doctors to diagnose the prostatic cancer.

Description

technical field [0001] The invention belongs to the technical field of medicine and biology, and in particular relates to a marker and a kit for auxiliary diagnosis of prostate cancer. Background technique [0002] Prostate cancer is one of the most common malignant tumors in men. According to global cancer statistics in recent years, there are about 1.3 million new prostate cancer patients around the world every year, and about 359,000 patients die. Prostate cancer It has become the second most common malignancy in males worldwide, after lung cancer. The incidence rate of prostate cancer in my country is also showing an obvious upward trend. According to the national malignant tumor survey data, the incidence rate of prostate cancer is 63.4%, and the mortality rate is 26.6%. The treatment of early prostate cancer is radical surgery, but because most early prostate cancer has no obvious symptoms and lacks specific diagnostic indicators, most patients are diagnosed with adva...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/6886C12N15/113A61K45/00A61K31/7105A61P35/00
CPCC12Q1/6886A61K45/00A61K31/7105A61P35/00C12Q2600/158C12Q2600/178
Inventor 仓顺东刘莉娜张钧硕李梦园郭燕万明会徐登飞
Owner PEOPLES HOSPITAL OF HENAN PROV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com